Business
Aelis Farma Reports Its 2025 Annual Financial Results and Confirms Its 2026 Outlook
BORDEAUX, France, March 30, 2026--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, today announces its full year results for the year ended December 31, 2025.
About this update from Aelis Farma Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":252,"url":"https://media.zenfs.com/en/business-wire.com/b84cb593d0e0d65e96869dd1fde536dd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GEHmHLktoQAEQl5IjumE5Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUwNA--/https://media.zenfs.com/en/business-wire.com/b84cb593d0e0d65e96869dd1fde536dd","width":480,"height":252}},"lazy":false},{"type":"text","content":"2025 has been marked by several significant events:","length":51,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The achievement of key milestones for the Company's two drug candidates:","length":76,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"AEF0117: announcement of the final results of the Phase 2b clinical study in cannabis use disorders","length":99,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"AEF0217: obtention of regulatory approvals and successful start of the recruitment of the Phase 2b clinical study for the treatment of behavioral and cognitive impairments of people with Down syndrome.","length":201,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":300,"olType":false}]},{"val":[{"type":"text","content":"Solid cash position of €9.1 million as of December 31, 2025, strengthened by new non-dilutive fundings and ensuring financial visibility until the beginning of 2028.","length":165,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":541,"olType":false},{"type":"text","content":"BORDEAUX, France, March 30, 2026--(BUSINESS WIRE)--Regulatory News:","length":67,"tagName":"p"},{"type":"text","content":"Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, today announces its full year results for the year ended December 31, 2025.","length":276,"tagName":"p"},{"type":"text","content":"Pier Vincenzo Piazza, CEO of Aelis Farma, stated: "The year 2025 was marked by further progress in the clinical development of our two drug candidates, AEF0117 and AEF0217. For AEF0117, the final results of the Phase 2b study in cannabis use disorder (CUD) demonstrated that...